

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2023/185778 A9

(43) International Publication Date
05 October 2023 (05.10.2023)

(51) International Patent Classification:

C07K 16/28 (2006.01) C12P 21/08 (2006.01)
C12N 15/13 (2006.01) A61K 39/395 (2006.01)
C12N 15/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2023/084213

(22) International Filing Date:

28 March 2023 (28.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/083269

28 March 2022 (28.03.2022) CN

(71) Applicant: **GENOR BIOPHARMA CO., LTD.** [CN/C-
N]; 1-4/F, Building 3, Lane 1690, Zhangheng Road, Chi-
na (Shanghai) Pilot Free Trade Zone, Pudong New Area,
Shanghai 201203 (CN).

(72) Inventors: **ZHOU, Tiantian**; 1-4/F, Building 3, Lane 1690,
Zhangheng Road, China (Shanghai) Pilot Free Trade Zone,
Pudong New Area, Shanghai 201203 (CN). **DU, Qinglin**;
1-4/F, Building 3, Lane 1690, Zhangheng Road, China
(Shanghai) Pilot Free Trade Zone, Pudong New Area,

Shanghai 201203 (CN). **HAN, Shuhua**; 1-4/F, Building
3, Lane 1690, Zhangheng Road, China (Shanghai) Pilot
Free Trade Zone, Pudong New Area, Shanghai 201203
(CN). **PENG, Fei**; 1-4/F, Building 3, Lane 1690, Zhangheng
Road, China (Shanghai) Pilot Free Trade Zone, Pudong
New Area, Shanghai 201203 (CN). **YANG, Xueyan**; 1-4/F,
Building 3, Lane 1690, Zhangheng Road, China (Shanghai)
Pilot Free Trade Zone, Pudong New Area, Shanghai 201203
(CN).

(74) Agent: **CHINA PATENT AGENT (H.K.) LTD.**; 22/F.,
Great Eagle Center, 23 Harbor Road, Wanchai, Hong Kong
999077 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: NOVEL ANTI-FGFR2 ANTIBODIES

B




Fig 2

(57) Abstract: Disclosed are anti-FGFR2b antibody or antigen-binding fragments thereof, nucleic acid encoding the same, pharmaceutical compositions comprising the same, method for producing the same, and the uses thereof.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the revised international search report:

02 November 2023 (02.11.2023)

(15) Information about Correction:

see Notice of 02 November 2023 (02.11.2023)